[Drug use by mentally handicapped persons in institutions and family-replacing residential facilities]. 1995

H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
Stichting Pepijnklinieken, Echt.

OBJECTIVE Description of use of medication by people with mental handicaps in relation to age, level of mental handicap and living facility. METHODS Cross-sectional study. METHODS Institutions and group homes for people with mental handicaps in North Brabant and Limburg, the Netherlands. METHODS Of a patient sample (n = 1265), stratified according to age and living facility (i.e. institution or group home) data were collected by means of questionnaires to be completed by the general practitioners. For 101 persons data about level of mental handicap were lacking. RESULTS 57% of the patients used one or more drugs. The numbers of drugs used were significantly related to (increased) age and level of mental handicap. Older patients more often used antipsychotics, laxatives and cardiovascular medication, younger ones more often used anticonvulsants. More severely handicapped persons used antipsychotics, anticonvulsants, laxatives, antacids, psychoactive medication and gastrointestinal medication more often. There was no relationship between amount of medication and living facility. CONCLUSIONS Many mentally handicapped use medication. Since epilepsy, psychiatric and behavioural diseases and gastrointestinal problems are frequent, and because the patients offer little spontaneous information, alertness with respect to drug interaction and side effects is indicated.

UI MeSH Term Description Entries
D008607 Intellectual Disability Subnormal intellectual functioning which originates during the developmental period. This has multiple potential etiologies, including genetic defects and perinatal insults. Intelligence quotient (IQ) scores are commonly used to determine whether an individual has an intellectual disability. IQ scores between 70 and 79 are in the borderline range. Scores below 67 are in the disabled range. (from Joynt, Clinical Neurology, 1992, Ch55, p28) Disability, Intellectual,Idiocy,Mental Retardation,Retardation, Mental,Deficiency, Mental,Intellectual Development Disorder,Mental Deficiency,Mental Retardation, Psychosocial,Deficiencies, Mental,Development Disorder, Intellectual,Development Disorders, Intellectual,Disabilities, Intellectual,Disorder, Intellectual Development,Disorders, Intellectual Development,Intellectual Development Disorders,Intellectual Disabilities,Mental Deficiencies,Mental Retardations, Psychosocial,Psychosocial Mental Retardation,Psychosocial Mental Retardations,Retardation, Psychosocial Mental,Retardations, Psychosocial Mental
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D011619 Psychotropic Drugs A loosely defined grouping of drugs that have effects on psychological function. Here the psychotropic agents include the antidepressive agents, hallucinogens, and tranquilizing agents (including the antipsychotics and anti-anxiety agents). Psychoactive Agent,Psychoactive Agents,Psychoactive Drug,Psychopharmaceutical,Psychopharmaceuticals,Psychotropic Drug,Psychoactive Drugs,Agent, Psychoactive,Agents, Psychoactive,Drug, Psychoactive,Drug, Psychotropic,Drugs, Psychoactive,Drugs, Psychotropic
D012112 Residential Facilities Long-term care facilities which provide supervision and assistance in activities of daily living with medical and nursing services when required. Facilities, Residential,Facility, Residential,Residential Facility
D002317 Cardiovascular Agents Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. Cardioactive Agent,Cardioactive Drug,Cardiovascular Agent,Cardiovascular Drug,Cardioactive Agents,Cardioactive Drugs,Cardiovascular Drugs,Agent, Cardioactive,Agent, Cardiovascular,Drug, Cardioactive,Drug, Cardiovascular
D003430 Cross-Sectional Studies Studies in which the presence or absence of disease or other health-related variables are determined in each member of the study population or in a representative sample at one particular time. This contrasts with LONGITUDINAL STUDIES which are followed over a period of time. Disease Frequency Surveys,Prevalence Studies,Analysis, Cross-Sectional,Cross Sectional Analysis,Cross-Sectional Survey,Surveys, Disease Frequency,Analyses, Cross Sectional,Analyses, Cross-Sectional,Analysis, Cross Sectional,Cross Sectional Analyses,Cross Sectional Studies,Cross Sectional Survey,Cross-Sectional Analyses,Cross-Sectional Analysis,Cross-Sectional Study,Cross-Sectional Surveys,Disease Frequency Survey,Prevalence Study,Studies, Cross-Sectional,Studies, Prevalence,Study, Cross-Sectional,Study, Prevalence,Survey, Cross-Sectional,Survey, Disease Frequency,Surveys, Cross-Sectional
D004363 Drug Utilization The utilization of drugs as reported in individual hospital studies, FDA studies, marketing, or consumption, etc. This includes drug stockpiling, and patient drug profiles. Utilization, Drug,Drug Utilizations,Utilizations, Drug
D005765 Gastrointestinal Agents Drugs used for their effects on the gastrointestinal system, as to control gastric acidity, regulate gastrointestinal motility and water flow, and improve digestion. Digestants,Gastric Agents,Gastric Drugs,Gastrointestinal Drugs,Agents, Gastric,Agents, Gastrointestinal,Drugs, Gastric,Drugs, Gastrointestinal
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
January 1985, Psychopharmacology bulletin,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
June 1991, TVZ : het vakblad voor de verpleging,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
September 1981, The British journal of psychiatry : the journal of mental science,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
December 1968, British medical journal,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
January 2004, Acta anaesthesiologica Belgica,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
November 1978, The New England journal of medicine,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
April 1981, Mental retardation,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
August 1981, Health trends,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
May 1981, American journal of mental deficiency,
H M van Schrojenstein Lantman-de Valk, and A G Kessels, and M J Haveman, and M A Maaskant, and H F Urlings, and M van den Akker
April 1960, British medical journal,
Copied contents to your clipboard!